SOP for TMF confidentiality – Clinical Research Made Simple

SOP for Confidentiality and Data Protection Controls

digi — Tue, 23 Sep 2025 19:41:00 +0000

SOP for Confidentiality and Data Protection Controls

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-confidentiality-and-data-protection-controls”
},
“headline”: “SOP for Confidentiality and Data Protection Controls”,
“description”: “This SOP establishes procedures for confidentiality and data protection controls in clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, GDPR, HIPAA, and ICH GCP requirements. It covers subject privacy, anonymization, encryption, secure data transfer, and breach management.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Confidentiality and Data Protection Controls

SOP No.	CR/OPS/094/2025
Supersedes	NA
Page No.	1 of 43
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Purpose

The purpose of this SOP is to define processes for maintaining confidentiality and implementing data protection controls in clinical trials. These measures ensure compliance with global data protection regulations, safeguard subject privacy, and protect trial data from unauthorized access, loss, or breaches.

Scope

This SOP applies to sponsors, CROs, investigators, site staff, vendors, and data management teams handling clinical trial records, including paper, electronic, and hybrid systems. It covers confidentiality agreements, anonymization, pseudonymization, encryption, data sharing, secure transfer, storage, and breach notification.

Responsibilities

Sponsor: Defines data protection policies and ensures oversight.
Investigator: Protects subject confidentiality at the site level.
QA: Audits confidentiality and data protection systems.
Data Management: Implements technical and organizational data security measures.
Vendors: Comply with sponsor confidentiality agreements and data security requirements.

Accountability

The Sponsor is accountable for ensuring global compliance with data protection laws. Investigators are accountable for safeguarding subject confidentiality at trial sites. QA ensures oversight and inspection readiness.

Procedure

1. Confidentiality Agreements
1.1 All staff, CROs, and vendors must sign confidentiality agreements before accessing trial data.
1.2 Agreements must include provisions for subject privacy, intellectual property, and proprietary data.

2. Subject Data Protection
2.1 Assign unique subject identifiers; do not use directly identifiable information in reports.
2.2 Anonymize or pseudonymize subject data before transfer or storage.
2.3 Maintain Subject Confidentiality Log (Annexure-1).

3. Data Security Controls
3.1 Implement encryption for electronic data at rest and during transfer.
3.2 Restrict access to data using role-based controls.
3.3 Document data access in Access Control Log (Annexure-2).

4. Secure Data Transfer
4.1 Use secure portals, encrypted emails, or validated EDC systems.
4.2 Record all data transfers in Data Transfer Log (Annexure-3).

5. Breach Notification
5.1 Report suspected or confirmed breaches within 24 hours to Sponsor and QA.
5.2 Initiate Breach Investigation Log (Annexure-4).
5.3 Notify regulatory authorities per GDPR/HIPAA requirements.

6. Archiving and Retention
6.1 Archive data in secure, access-controlled facilities or validated eArchives.
6.2 Retain confidentiality documentation as per regulatory timelines.

7. Training
7.1 All staff handling subject data must undergo annual training on confidentiality and data protection.
7.2 Training must be documented in Training Log (Annexure-5).

Abbreviations

SOP: Standard Operating Procedure
QA: Quality Assurance
CRO: Contract Research Organization
EDC: Electronic Data Capture
GDPR: General Data Protection Regulation
HIPAA: Health Insurance Portability and Accountability Act
TMF: Trial Master File
ISF: Investigator Site File

Documents

Subject Confidentiality Log (Annexure-1)
Access Control Log (Annexure-2)
Data Transfer Log (Annexure-3)
Breach Investigation Log (Annexure-4)
Training Log (Annexure-5)

References

Version: 1.0

Approval Section

Prepared By	Ravi Kumar, Data Protection Officer
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head Clinical Quality

Annexures

Annexure-1: Subject Confidentiality Log

Date	Subject ID	Data Handling Method	Responsible
01/09/2025	SUBJ-501	Anonymized before transfer	Data Manager

Annexure-2: Access Control Log

Date	User	Role	Data Accessed	Authorized By
05/09/2025	Meena Sharma	CRA	eCRF	Data Manager

Annexure-3: Data Transfer Log

Date	Data Set	Method	Sender	Receiver
10/09/2025	PK Dataset	Secure Portal	Site Coordinator	Sponsor Data Manager

Annexure-4: Breach Investigation Log

Date	Incident	Reported By	Action Taken	Status
12/09/2025	Unauthorized access attempt	QA Officer	Blocked user, reported to Sponsor	Closed

Annexure-5: Training Log

Date	Name	Role	Training Topic	Trainer
01/09/2025	Ravi Kumar	Data Manager	GDPR and HIPAA	QA Officer

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head Clinical Quality

For more SOPs visit: Pharma SOP

SOP for TMF Access, Permissions, and Security

digi — Mon, 15 Sep 2025 15:45:18 +0000

SOP for TMF Access, Permissions, and Security

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-tmf-access-permissions-and-security”
},
“headline”: “SOP for TMF Access, Permissions, and Security”,
“description”: “This SOP outlines standardized procedures for managing access, permissions, and security for Trial Master Files (TMF/eTMF), ensuring compliance with ICH GCP, FDA, EMA, CDSCO, and WHO requirements. It covers user roles, authentication, password policies, inspector access, and access control logs.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for TMF Access, Permissions, and Security

SOP No.	CR/OPS/079/2025
Supersedes	NA
Page No.	1 of 38
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Purpose

The purpose of this SOP is to define processes for managing access, permissions, and security of Trial Master Files (TMF/eTMF), ensuring that only authorized personnel have appropriate access in compliance with ICH GCP, 21 CFR Part 11, EMA Annex 11, CDSCO, and WHO requirements.

Scope

This SOP applies to all sponsor, CRO, site, and vendor staff accessing TMF/eTMF systems. It covers user role assignment, authentication, inspector access, account lifecycle management, password and security policies, access logging, and oversight responsibilities.

Responsibilities

Sponsor: Owns responsibility for TMF/eTMF access policies and oversight.
TMF Administrator: Assigns roles, manages permissions, monitors access logs.
IT/System Administrator: Maintains system security, authentication controls, and audit trails.
QA: Audits TMF access practices for compliance.
Users: Maintain confidentiality, follow password and access policies, and report incidents.

Accountability

Head of QA is accountable for overall TMF/eTMF security and compliance. TMF Administrator is accountable for user access accuracy and timeliness. IT is accountable for system security controls.

Procedure

1. User Role Definition
1.1 Define TMF user roles (Admin, Contributor, Reviewer, Read-only).
1.2 Maintain TMF Permission Matrix (Annexure-1).
1.3 Assign access based on “least privilege” principle.

2. Access Requests
2.1 Users submit Access Request Form (Annexure-2).
2.2 Requests approved by line manager and QA.
2.3 TMF Administrator assigns access within 2 working days.

3. Authentication Controls
3.1 All accounts must have unique usernames and strong passwords (minimum 8 characters, complexity requirements).
3.2 Multi-factor authentication (MFA) must be enabled for remote access.
3.3 Passwords expire every 90 days and must not be reused for 5 cycles.

4. Inspector Access
4.1 Regulatory inspectors may be granted read-only access during inspections.
4.2 Access must be time-bound and logged in Inspector Access Log (Annexure-3).
4.3 Inspector accounts must be deactivated immediately after inspection closure.

5. Account Lifecycle Management
5.1 Accounts must be reviewed every 6 months.
5.2 Access must be revoked within 1 working day of employee leaving project.
5.3 All account changes logged in Access Control Log (Annexure-4).

6. Access Monitoring
6.1 IT and QA review access logs monthly.
6.2 Suspicious access attempts must be investigated within 24 hours.
6.3 Findings documented in Security Incident Log (Annexure-5).

7. Confidentiality and Security
7.1 All users must sign confidentiality agreements.
7.2 Data exports must be encrypted and logged.
7.3 Unauthorized access attempts result in account suspension.

Abbreviations

SOP: Standard Operating Procedure
TMF/eTMF: Trial Master File / electronic Trial Master File
QA: Quality Assurance
IT: Information Technology
MFA: Multi-Factor Authentication

Documents

TMF Permission Matrix (Annexure-1)
Access Request Form (Annexure-2)
Inspector Access Log (Annexure-3)
Access Control Log (Annexure-4)
Security Incident Log (Annexure-5)

References

Version: 1.0

Approval Section

Prepared By	Ravi Kumar, TMF Administrator
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head Clinical Quality

Annexures

Annexure-1: TMF Permission Matrix

Role	Access Rights
Admin	Create/Edit/Delete
Contributor	Create/Edit
Reviewer	Read/Edit Comments
Read-only	View only

Annexure-2: Access Request Form

Name	Role Requested	Justification	Approved By	Date
Meena Sharma	Contributor	CRA filing access	QA Manager	05/09/2025

Annexure-3: Inspector Access Log

Date	Inspector Name	Agency	Access Duration	Status
15/09/2025	John Smith	FDA	3 days	Closed

Annexure-4: Access Control Log

Date	User	Action	Performed By
12/09/2025	Arjun Patel	Access Revoked	TMF Admin

Annexure-5: Security Incident Log

Date	Incident	Reported By	Action Taken	Status
20/09/2025	Failed login attempts	System Admin	Account locked	Resolved

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head Clinical Quality

For more SOPs visit: Pharma SOP